{"disease":{"id":"nsclc-non-small-cell-lung-carcinoma","name":"nsclc non small cell lung carcinoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06881784","title":"Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":420,"lead_sponsor_name":"Revolution Medicines, Inc.","has_results":false},{"nct_id":"NCT04585750","title":"The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"PMV Pharmaceuticals, Inc","has_results":false},{"nct_id":"NCT05456867","title":"A Multi-center, Non-interventional, Prospective Study of Durvalumab in Unresectable Locally Advanced NSCLC in Routine Clinical Practice in Russia","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":250,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT06682793","title":"A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":240,"lead_sponsor_name":"A2 Biotherapeutics Inc.","has_results":false},{"nct_id":"NCT07219251","title":"Engagement of Veterans With Lung Cancer","phase":"NA","overall_status":"RECRUITING","enrollment_count":194,"lead_sponsor_name":"Palo Alto Veterans Institute for Research","has_results":false},{"nct_id":"NCT07050043","title":"Low Dose Nivolumab With Chemotherapy vs Standard Chemotherapy as First-Line Treatment in Advanced or Metastatic NSCLC","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":123,"lead_sponsor_name":"Dr Arvindran A/L Alaga","has_results":false},{"nct_id":"NCT03444766","title":"Study of Nivolumab for Advanced Cancers in India","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":true},{"nct_id":"NCT02119650","title":"Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":76,"lead_sponsor_name":"Incyte Corporation","has_results":true},{"nct_id":"NCT07182708","title":"High-Dose Firmonertinib Plus Bevacizumab as Neoadjuvant Therapy for Resectable EGFRm Stage II-IIIB NSCLC","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":62,"lead_sponsor_name":"Peking University Cancer Hospital & Institute","has_results":false},{"nct_id":"NCT06694454","title":"Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":60,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06685718","title":"A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":33,"lead_sponsor_name":"BeOne Medicines","has_results":false},{"nct_id":"NCT06951399","title":"Tracking T-Cell Responses to Evaluate Pembrolizumab Effectiveness in Advanced Non-Small Cell Lung Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":30,"lead_sponsor_name":"Rabin Medical Center","has_results":false},{"nct_id":"NCT07314216","title":"Firmonertinib Combined With Definitive Radiotherapy in Stage III Unresectable EGFR Uncommon Mutant Pulmonary Adenocarcinoma","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":15,"lead_sponsor_name":"Hunan Cancer Hospital","has_results":false},{"nct_id":"NCT03758781","title":"IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":12,"lead_sponsor_name":"H. Lee Moffitt Cancer Center and Research Institute","has_results":false},{"nct_id":"NCT07106827","title":"A Study of GV20-0251 in Advanced or Refractory Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":10,"lead_sponsor_name":"West China Hospital","has_results":false}],"total":15},"guidelines":[],"source":"Drug Landscape verified database"}